A-56268 is a 6-O-methyl derivative of erythromycin A which has a spectrum of activity similar to that of erythromycin and is 1 log2 dilution more potent than erythromycin against most organisms that have been tested. The correlation of zone size diameters and MICs of A-56268 for 461 strains of bacteria isolated from clinical specimens was investigated. Based on anticipated levels in human serum of 2 ,ug/ml, 15-,ug A new macrolide, A-56268 (TE-031), was tested against a variety of gram-positive bacteria and selected gram-negative bacteria. The structure of the compound and its microbiological activity have been described previously (4). It is similar to erythromycin except that A-56268 is methylated at the 6-hydroxy position of the macrolide ring. Comparison of zone sizes and MICs of A-56268 against 461 strains of bacteria isolated from clinical specimens was made, and tentative interpretative standards for disk diffusion and broth dilution susceptibility testing with A-56268 were selected. Erythromycin was used as a reference macrolide to evaluate the activity of A-56268.
. The purity of the cultures was established, and the identity of most of the organisms was confirmed with identification systems (Analytab Products, Plainview, N.Y.). Those organisms that could not be identified by this method were identified by recommended procedures described in the Manual of Clinical Microbiology (2, 3, 6) .
Drug source and preparation. The compounds used in this study were A-56268 and erythromycin (Abbott). Stock solutions were prepared by dissolving the compounds in a minimal amount of methanol and diluting to 2,000 ,ug/ml with 0.1 M phosphate buffer (pH 8.0) for erythromycin and 0.1 M phosphate buffer (pH 6.8) for A-56268.
Disk preparation. Erythromycin disks impregnated with antibiotics, as recommended by the National Committee for Clinical Laboratory Standards (NCCLS) (7) for disk diffusion susceptibility testing, were purchased from BBL Microbiology Systems, Cockeysville, Md. A-56268 was not available commercially and was prepared in our laboratory by pipetting 20 ,ul of a solution containing the desired concentration of antibiotic to blank filter paper disks (0.25 inch [0.64 cm] grade 740-E; Schleicher & Schuell, Inc., Keene, N.H.). The optimal drug content per disk for A-56268 was determined by testing disks containing 5.0, 10.0, 15.0, 20.0, and 25.0 Ftg of drug per disk on 113 strains of bacteria isolated from clinical sources. Disks that were impregnated with antibiotics were stored at -65°C. The stability of the antibiotic disks was closely monitored by observing the daily reproducibility of zone sizes with the reference strains.
Testing procedures. The MICs of the antibiotics were determined by the agar dilution procedure by using MuellerHinton agar as described by the NCCLS (8) .
In both the agar dilution procedure and the disk diffusion test (see below), all Listeria and Streptococcus species were tested on Mueller-Hinton medium supplemented with 5%o defibrinated sheep blood (GIBCO Diagnostics, Madison, 
Wis.). Enterococcus and Staphylococcus species were tested on nonsupplemented Mueller-Hinton agar (GIBCO).
In vitro antimicrobial susceptibility testing by the disk diffusion method was done by the recommendations of the NCCLS (7). Duplicate zone sizes were determined for each organism and antibiotic. The mean value rounded to the nearest whole millimeter was then calculated for the duplicate zone sizes. The agar dilution test was controlled by including Staphylococcus aureus ATCC 29213 and Streptococcus faecalis ATCC 29212. The disk susceptibility test was controlled by using Staphylococcus aureus ATCC 25923. The acceptable control limits were as described previously (7, 8) .
Statistical analysis. By using the method of ordinary leastsquares analysis, estimates of the regression line and correlation coefficient were obtained by regressing the MIC on the zone diameter. For preliminary regression analysis, organisms exhibiting an MIC -0.031 ,ug/ml were assigned a value of 0.031 Ftg/ml, and organisms exhibiting an MIC .64.0 ,ug/ml were assigned a value of 64.0 tg/Iml. In addition, a zone diameter of <7 mm was assigned a value of 6 mm. For each of the conipounds, the correlation coefficient, mean MIC, mean zone diameter, and regression line were calculated. The data used in this analysis were plotted according to the frequency of organisms with the same MIC and zone diameter. Breakpoints for resistance and susceptibility were tentatively chosen partly on the basis of the calculation's described above, probable achievable levels in serum, and the similarity of A-56268 to erythromycin.
Regression analysis was repeated by using only on-scale measurements (i.e., excluding MICs <0.031 or -64.0 ,ug/ml and zone diameters <7 or >40 mm) (9) . The regression line that was computed by using these data was y = 11.80 -0.231x (where y = log2 MIC + 8, and x = zone diameter). From these results the zone susceptibility testing criteria for A-56268 would be .12 mm for the susceptible breakpoint with no resistant breakpoint. Therefore, this method was not used to determine breakpoints for A-56268.
To assess the linearity of the regression line near the MIC breakpoints, regression statistics were calculated for these compounds for the MIC intervals of 2 to 3 log2 dilutions above and below these breakpoints (9) . The MIC intervals that were used in this analysis were as follows: (i) 0 
RESULTS AND DISCUSSION
Selection of optimum drug content in disks to be used for diffusion susceptibility tests with A-56268. The optimum drug content of A-56268 per disk was determined by testing 113 clinical isolates with antibiotic disks containing 5.0, 10.0, 15.0, 20.0, and 25.0 ,ug of drug. The MICs for these organisms were also determined. The inhibitory zone sizes versus MICs for each isolate were plotted, and a regression line was calculated. Disks containing erythromycin were treated in a similar manner for comparative purposes, The slope, intercept, and correlation coefficient for the disk containing 15 ,ug of A-56268 were similar to those values for the disk containing 15 ,ug of erythromycin as recommended by the NCCLS (Table 1) ; and because of the similarities of the two drugs, the 15-,ug disk was used for subsequent studies.
Regression analysis of MICs and zone sizes from A-56268 against 461 clinical isolates. To more thoroughly evaluate A-56268, MIC and duplicate zone size determinations were made for an additional 461 strains of Staphylococcus, Streptococcus, Enterococcus, and Listeria species derived from clinical sources. For reference purposes, the orgainisms were also tested against érythromycin. The results from the statistical analysis for those determinations against all organisms tested are shown in Table 2 . The slope, y intercept, and correlation coefficient for A-56268 corresponded closely to those values for erythromycin. The differences in mean zone sizes and mean MICs for A-56268 and erythromycin were not statistically significant. Also shown in Table 2 is the regression analysis with data from two dilutions above the MIC for resistance of 8.0 p.g/ml to three dilutions below the MIC breakpoint for susceptibility of 0.5 ,ug/ml for erythromycin (8) and 2.0 ,ug/ml for A-56268. Within these constraints, significantly more strains were included in the analysis for erythromycin than in the analysis for A-56268. This difference between A-56268 and erythromycin is related to the fact that the MIC breakpoint for susceptibility to erythromycin was s0.5 ,ug/ml and the breakpoint for susceptibility to A-56268 was selected as 2 ,ug/ml. If the MIC correlate for susceptibility to erythromycin (2 ,ug/ml) were used instead of the MIC for susceptibility, then the values for erythromycin and A-56268 would be similar.
Based on anticipated levels in human serum of at least 2.0 ,ug/ml, an MIC of s2.0 ,ug/ml was chosen as the MIC level for susceptibility and .8.0 ,ug/ml was chosen as the MIC level for resistance to A-56268 (Fig.1) . We It should be emphasized that these interpretative criteria for A-56268 are tentative and could be altered on the basis of data from clinical trials. For comparative purposes, published interpretative criteria for erythromycin (1) use .13 and .18 mm, respectively, as zone sizes for resistance and susceptibility. The MIC correlates are .8 and s<2 ,ug/ml, respectively. Those breakpoints for erythromycin divide the 461 organisms tested into 0% false susceptible, 0.22% false resistarft, and 3. closely correspond to achievable levels of that antibiotic in serum. These proposed changes result in error rates of 0% false susceptible, 0% false resistant, and 11.06% intermediate.
The interpretative criteria suggested by the NCCLS for A-56268 MICs are in agreement with those presented here. The NCCLS has recommended a zone breakpoint for susceptibility of 17 mm instead of 15 mm, as described here on the basis of the regression analysis alone. The error ratebounded method was not considered. We believe that both methods should be used in selecting interpretative criteria.
Serum pharmacokinetics were also used to determine the MIC breakpoints for susceptibility and resistance to A-56268. The breakpoints for susceptibility and resistance of -2.0 and -8.0 ,ugIml, respectively, are consistent with peak levels in serum of approximately 2.0 ,ug/ml and an area under the serum curve of 6.3 ,ug. h/ml, which were achieved following a single oral dose of 400 419, 1986 ). This is twice the peak level of erythromycin in serum for which the area under the serum curve is only 2.3 ptg* h/ml.
The mode and range (calculated from the mode ± 1 log2 dilution) of the MICs for the reference organisms calculated from 41 observations are shown in Table 3 . The mean zone size and range (calculated by using the mean + 2 standard deviations) for the reference organisms calculated from 37 observations are also shown in Table 3 .
Direct comparison of zone sizes and MICs of A-56268 and erythromycin. For purposes of these analyses, all off-scale measurements have been excluded from consideration. For graphical purposes, however, all data have been plotted. Regression analysis in which MICs of A-56268 and erythromycin were compared resulted in a correlation coefficient of 0.90. The regression line for these data (n = 245) was computed to be y = 0.68 + 0.781x (y = 10g2 MIC + 8 for A-56268 and x = log2 MIC + 8 for erythromycin). The mean MIC of A-56268 was 0.19 ,ug/ml, and that of erythromycin was 0.32 ,ug/ml. Regression analysis in which zone sizes of A-56268 were compared with those of erythromycin resulted in a correlation coefficient of 0.96. The regression line for these data (n = 347) was calculated to be y = 2.41 + 0.955x (theoretically, y = x), where y is the zone size for A-56268 and x is the zone size for erythromycin. The mean zone size for A-56268 was 28.06 mm, and that for erythromycin was
